Welcome to our dedicated page for Propanc Bio news (Ticker: PPCB), a resource for investors and traders seeking the latest updates and insights on Propanc Bio stock.
Propanc Biopharma, Inc. (PPCB) generates news that spans oncology research, clinical development, corporate finance, and its emerging digital asset strategy. As a biopharmaceutical company focused on proenzyme-based therapies for recurrent and metastatic cancer, Propanc’s updates often center on its lead candidate PRP, a combination of pancreatic proenzymes designed to target cancer stem cells, modulate epithelial-to-mesenchymal transition (EMT), and influence the tumor microenvironment.
News coverage commonly highlights scientific and clinical milestones, including preclinical findings in pancreatic ductal adenocarcinoma (PDAC) models, publications with academic collaborators, and plans for a Phase 1b First-In-Human study in patients with advanced solid tumors. Press releases describe how PRP may affect cancer-associated fibroblasts, tumor angiogenesis, cell migration, and chemosensitivity, as well as its potential relevance to chronic conditions such as fibrosis.
Investors following PPCB can also expect corporate and financial updates, such as details of the company’s Nasdaq listing, public offerings, and structured financing agreements. Recent announcements have described a private placement facility of up to $100 million in Series C Preferred Stock and warrants, intended to support both the R&D pipeline and a strategy to build a digital asset treasury through potential acquisitions of digital asset treasury companies.
Additional news items address intellectual property developments, including new patent filings for methods of treating resistant cancers and fibrosis, and extensions of Propanc’s POP1 joint research program with the Universities of Jaén and Granada. Together, these releases provide insight into how the company is advancing its proenzyme technology, expanding its patent estate, and structuring its balance sheet.
For readers tracking PPCB, the news stream offers a consolidated view of scientific progress, trial planning, financing transactions, and strategic initiatives that shape Propanc Biopharma’s evolution as a development-stage oncology company.
Propanc Biopharma (Nasdaq: PPCB) announced preclinical results for its lead proenzyme therapy PRP, reporting >85% tumor growth inhibition in pancreatic cancer models and plans for Phase 1b First‑In‑Human trials in 2026. The company cited PRP's chemo‑sensitizing effects, reduced fibrosis, stem‑cell targeting, and a $100M facility to support development.
Propanc positions PRP as a potential therapy for advanced solid tumors with initial focus on pancreatic and ovarian cancers; human efficacy and regulatory outcomes remain pending.
Propanc Biopharma (Nasdaq: PPCB) executed a service agreement with FyoniBio to develop and validate an LC-MS pharmacokinetics (PK) assay for its lead asset PRP (trypsinogen and chymotrypsinogen plus activated enzymes) to support a Phase 1b First‑In‑Human study in advanced solid tumor patients. The assay aims for ≤0.1µg/mL sensitivity to quantify four serum analytes. Propanc cites assay validation, GMP manufacture of PRP, and a clinical trial application as three key preparatory activities, and plans to commence the FIH study in the fourth calendar quarter of 2026.
Propanc Biopharma (Nasdaq: PPCB) highlights preclinical and near‑term clinical plans for lead asset PRP, an investigational proenzyme therapy targeting metastatic solid tumors. Key points: >85% tumor growth inhibition in pancreatic models, FDA Orphan Drug status for pancreatic cancer, a $100M funding facility, new patents, and a planned Phase 1b first‑in‑human trial in 2026 for 30–40 advanced solid tumor patients.
The company positions PRP as a multi‑targeted approach that may sensitize tumors, reduce fibrosis and resistance markers, and potentially lower toxicity versus standard therapies.
Propanc Biopharma (Nasdaq: PPCB) provided a corporate update and half yearly results to Dec 31, 2025. Highlights include four provisional patent filings expected to expand IP from ~90 to >200 patents, a peer‑reviewed publication on PRP in PDAC fibroblasts, and a private placement facility up to $100 million.
Financials: total assets $15.11M, convertible notes reduced to $55,000, quarter‑end cash $561,237, and initial proceeds of $1.5M received under the Series C facility.
Propanc Biopharma (Nasdaq: PPCB) highlighted its lead proenzyme therapy PRP, an IV combination of trypsinogen and chymotrypsinogen targeting cancer stem cells, EMT, angiogenesis and metastasis. Preclinical studies showed >85% tumor growth inhibition. FDA Orphan Drug Designation for pancreatic cancer was granted in 2017. A Phase 1b first-in-human study of ~30–40 patients is planned for 2026, with provisional patents and IP grants supporting formulations and production methods. Market estimates cited a $3.25B pancreatic cancer market in 2025, rising to $3.70B in 2026 and to $10.25B by 2034.
Propanc Biopharma (Nasdaq: PPCB) on Jan 27, 2026 filed a fourth provisional patent application in two months with IP Australia covering improved formulations of pancreatic proenzymes trypsinogen and chymotrypsinogen, the active components of its lead asset PRP. The filing targets stability, storage, freeze/thaw resilience and global transport challenges for proenzyme pharmaceutical compositions used in cancer and chronic diseases.
The company said these provisional filings, as they move to national phase entry, are expected to expand its patent estate from ~90 to >200 patents across compositions, formulations, treatment methods and indications, and support preparations for a Phase 1b first-in-human study in advanced cancer patients.
Propanc Biopharma (NASDAQ:PPCB) filed a new provisional patent application with IP Australia on January 20, 2026 for methods to produce fully synthetic recombinant trypsinogen and chymotrypsinogen (Rec-PRP).
The filing describes an optimized yeast-based expression system to manufacture a world-first fully synthetic version of PRP intended as a long-term therapy to treat and prevent metastatic cancer from solid tumors. Management says Rec-PRP could enable long shelf life without refrigeration, scalable lot-consistent supply without animal sourcing, and improved global distribution. The release cites a projected global metastatic cancer market of $111 billion by 2027 and frames the provisional as the third filing in two months to expand the company IP portfolio ahead of national phase filings worldwide.
Propanc Biopharma (Nasdaq: PPCB) described preclinical and market context for its pancreatic proenzyme candidate PRP and outlined next steps toward human studies in 2026. Key facts: PRP is a 1:6 mixture of trypsinogen and chymotrypsinogen; preclinical models showed tumor growth inhibition >85% at some doses and reduced EMT, angiogenesis, and fibrosis; FDA granted Orphan Drug Designation (2017). The company is pre-revenue, raised ~$4M in a recent IPO, and cited a potential $100M private placement facility to fund development. Phase I/II trials are planned for 2026.
Propanc Biopharma (Nasdaq: PPCB) provided a shareholder update on Jan 13, 2026 outlining 2025 progress and 2026 plans. The company said it will advance lead candidate PRP into a Phase 1b First‑In‑Human study in ~30–40 patients with advanced solid tumors at Peter MacCallum Cancer Centre in 2026. Propanc reported it raised $4 million after up‑listing to Nasdaq to fund clinical preparations, has invested over $30 million since inception, and holds an IP portfolio of 90+ issued patents. The update also described preclinical work on a synthetic backup Rec‑PRP and research into PRP for fibrosis, with key clinical manufacturing and PK method milestones expected by Q3 2026.
Propanc Biopharma (Nasdaq: PPCB) and partners published peer‑reviewed results in Scientific Reports (Dec 22, 2025) on the impact of pancreatic proenzymes (PRP) on pancreatic ductal adenocarcinoma (PDAC) fibroblasts.
The study reports that PRP, composed of bovine trypsinogen and chymotrypsinogen, exerts multifaceted effects on cancer‑associated fibroblasts (CAFs) and tumor cells and is described as a potential disruptor of the tumor microenvironment (TME). The company plans a Phase 1b clinical study in advanced solid‑tumor patients in Q3 2026 to determine a Phase 2 dose, with PDAC as a target indication.